Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02091986 · ClinicalTrials.gov registry record · Phase 3
A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 882
- Enrollment target
NCT02091986: Completed Phase 3 study, sponsored by AstraZeneca.
NCT02091986 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 882 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02091986, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 882 participants
- Enrollment target
Study Summary
The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to \<12 Years with Asthma during 12 weeks.
Primary Outcome
1h post-dose FEV1 is defined as the 1-hour post-dose measurement taken at Week 12 minus the pre dose measurement taken at randomization for patients who remain in the study (irrespective of whether IP has been discontinued).
Interventions
- DRUG Symbicort pMDI
- OTHER Budesonide pMDI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 882 participants |
| Start Date | 2014-04 |
| Est. Completion | 2016-04 |
| Phase | Phase 3 |
What the finished NCT02091986 record still lists
NCT02091986 is an interventional study that assigns participants to a tested intervention. The registered 882 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which Symbicort pMDI is the first listed.
NCT02091986 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02091986 about?
NCT02091986 is a clinical study titled "A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg". The purpose is to investigate the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared with Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to \<12 Years with Asthma during 12 weeks.
What is the current status of trial NCT02091986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 882 participants. The study started on 2014-04. Estimated completion is 2016-04.
What interventions are being tested in trial NCT02091986?
The interventions under investigation include: Symbicort pMDI (DRUG), Budesonide pMDI (OTHER).
Who is sponsoring clinical trial NCT02091986?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02091986's enrollment target sits among peer trials
882 366th of 2000 higher than 1,634 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- NCT05174286 · 880 participants · NA
Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
- NCT05454280 · 880 participants · Phase 3
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
- NCT05525663 · 880 participants · NA
Physical Rehabilitation for Older Patients With Acute Heart Failure With Preserved Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia